Spero Therapeutics, Inc. (SPRO)
Pharmaceutical Preparations
Latest Price
$1.17
TTM P/E
4.33
Normalized P/E
--
Div Yield
--
Book Value
0.92
P/B Ratio
1.27
Valuation metrics
adjust assumptions →EPS: $0.15
Book value / share: $1.05
Formula: √(22.5 × EPS × BVPS)
Graham Number
$1.88
+61% upside
EPS: $0.15
Target P/E: 4×
Formula: EPS × P/E
P/E Fair Value
$0.60
49% downside
Institutional Ownership
33.4% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| GSK plc | 9.19M | $21.0M | 15.88% | -- | 2026-03-31 |
| Pfizer Inc | 2.36M | $5.0M | 4.08% | -- | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.80M | $4.0M | 3.11% | -- | 2026-03-31 |
| RENAISSANCE TECHNOLOGIES LLC | 1.19M | $2.0M | 2.05% | -90.3K | 2026-03-31 |
| Alphabet Inc. | 890.0K | $2.0M | 1.54% | -- | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 519.9K | $1.0M | 0.90% | -9.3K | 2026-03-31 |
| BlackRock, Inc. | 433.2K | $1.0M | 0.75% | -414 | 2026-03-31 |
| CITADEL ADVISORS LLC | 425.7K | -- | 0.74% | -45.3K | 2026-03-31 |
| Anson Funds Management LP | 422.0K | -- | 0.73% | -203.1K | 2026-03-31 |
| GSA CAPITAL PARTNERS LLP | 278.3K | -- | 0.48% | +99.4K | 2026-03-31 |